HSBC Holdings’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10M | Buy |
13,000
+10,600
| +442% | +$8.12M | 0.01% | 933 |
|
|
2025
Q4 | $1.86M | Buy |
+2,400
| New | +$1.63M | ﹤0.01% | 1598 |
|
|
2025
Q1 | – | Sell |
-19,400
| Closed | -$13.7M | – | 3223 |
|
|
2024
Q4 | $13.7M | Sell |
19,400
-5,700
| -23% | -$4.78M | 0.01% | 827 |
|
|
2024
Q3 | $26.2M | Hold |
25,100
| – | – | 0.02% | 655 |
|
|
2024
Q2 | $26.3M | Sell |
25,100
-6,100
| -20% | -$5.91M | 0.02% | 613 |
|
|
2024
Q1 | $30M | Sell |
31,200
-14,900
| -32% | -$14.2M | 0.02% | 590 |
|
|
2023
Q4 | $40.5M | Buy |
46,100
+4,300
| +10% | +$3.54M | 0.04% | 475 |
|
|
2023
Q3 | $34.4M | Buy |
41,800
+5,400
| +15% | +$4.24M | 0.04% | 479 |
|
|
2023
Q2 | $25.9M | Buy |
36,400
+22,400
| +160% | +$17.3M | 0.03% | 558 |
|
|
2023
Q1 | $11.4M | Buy |
14,000
+12,500
| +833% | +$9.43M | 0.01% | 800 |
|
|
2022
Q4 | $1.07M | Hold |
1,500
| – | – | ﹤0.01% | 1934 |
|
|
2022
Q3 | $1.05M | Sell |
1,500
-1,400
| -48% | -$881K | ﹤0.01% | 1810 |
|
|
2022
Q2 | $1.73M | Buy |
2,900
+2,600
| +867% | +$1.69M | ﹤0.01% | 1651 |
|
|
2022
Q1 | $212K | Sell |
300
-2,300
| -88% | -$1.46M | ﹤0.01% | 2970 |
|
|
2021
Q4 | $1.66M | Sell |
2,600
-2,300
| -47% | -$1.41M | ﹤0.01% | 1773 |
|
|
2021
Q3 | $2.98M | Sell |
4,900
-100
| -2% | -$62.1K | ﹤0.01% | 1372 |
|
|
2021
Q2 | $2.8M | Sell |
5,000
-304,400
| -98% | -$154M | ﹤0.01% | 1307 |
|
|
2021
Q1 | $146M | Buy |
309,400
+281,800
| +1,021% | +$137M | 0.17% | 116 |
|
|
2020
Q4 | $13.1M | Buy |
27,600
+6,800
| +33% | +$3.67M | 0.02% | 712 |
|
|
2020
Q3 | $11.8M | Hold |
20,800
| – | – | 0.02% | 662 |
|
|
2020
Q2 | $13M | Sell |
20,800
-9,800
| -32% | -$5.56M | 0.02% | 562 |
|
|
2020
Q1 | $14.8M | Buy |
30,600
+7,600
| +33% | +$3.13M | 0.03% | 457 |
|
|
2019
Q4 | $8.6M | Sell |
23,000
-18,300
| -44% | -$6.16M | 0.01% | 879 |
|
|
2019
Q3 | $11.5M | Sell |
41,300
-600
| -1% | -$178K | 0.02% | 787 |
|
|
2019
Q2 | $13.1M | Buy |
41,900
+18,400
| +78% | +$6.13M | 0.02% | 698 |
|
|
2019
Q1 | $9.65M | Sell |
23,500
-11,300
| -32% | -$4.65M | 0.02% | 824 |
|
|
2018
Q4 | $13M | Buy |
34,800
+7,700
| +28% | +$2.82M | 0.02% | 685 |
|
|
2018
Q3 | $10.9M | Buy |
27,100
+11,500
| +74% | +$4.38M | 0.02% | 816 |
|
|
2018
Q2 | $5.38M | Buy |
15,600
+1,800
| +13% | +$563K | 0.01% | 1084 |
|
|
2018
Q1 | $4.75M | Buy |
+13,800
| New | +$4.8M | 0.01% | 1126 |
|
|
2017
Q4 | – | Sell |
-15,200
| Closed | -$6.8M | – | 2330 |
|
|
2017
Q3 | $6.8M | Buy |
15,200
+3,200
| +27% | +$1.52M | 0.01% | 932 |
|
|
2017
Q2 | $5.89M | Buy |
+12,000
| New | +$5.25M | 0.01% | 929 |
|
|
2016
Q3 | – | Sell |
-5,000
| Closed | -$1.75M | – | 2107 |
|
|
2016
Q2 | $1.75M | Sell |
5,000
-2,500
| -33% | -$963K | ﹤0.01% | 1220 |
|
|
2016
Q1 | $2.7M | Buy |
7,500
+2,500
| +50% | +$1.03M | 0.01% | 1078 |
|
|
2015
Q4 | $2.71M | Buy |
+5,000
| New | +$2.71M | 0.01% | 1165 |
|
Other funds holding REGN
VCM
N
HSBC Holdings's REGN Position: Q1 2026 in Review
HSBC Holdings increased its Regeneron Pharmaceuticals (REGN) stake by 1.4% in Q1 2026, buying an estimated $3.47M and bringing the position to 323,338 shares worth $250M. The position accounts for 0.13% of the portfolio, ranked #148.
HSBC Holdings first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $384M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- HSBC Holdings held 323,338 shares of Regeneron Pharmaceuticals worth $250M as of Q1 2026.
- HSBC Holdings bought 4,530 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $3.47M.
- Regeneron Pharmaceuticals made up 0.13% of HSBC Holdings's portfolio in Q1 2026, its #148 holding.
- HSBC Holdings first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- HSBC Holdings's Regeneron Pharmaceuticals position peaked at $384M in Q2 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.